Hutchison China Meditech Limited Block Admission Applications & Total Voting Rights (9447B)
June 12 2019 - 3:18AM
UK Regulatory
TIDMHCM
RNS Number : 9447B
Hutchison China Meditech Limited
12 June 2019
Block Admission Applications and Total Voting Rights
London: Wednesday, June 12, 2019: Hutchison China MediTech
Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that the
following applications have been made to the London Stock Exchange
plc for the block admission of ordinary shares, par value of
US$0.10 each ("Ordinary Shares") to be admitted to trading on
AIM:
(i) an application for a block admission of 2,067,910 Ordinary
Shares to be admitted to trading on AIM to be issued from time to
time pursuant to the exercise of share options under the Share
Option Scheme conditionally adopted by Chi-Med in 2005 (the "2005
HCML Share Option Scheme"). It is expected that such admission will
become effective on June 17, 2019.
(ii) an application for a block admission of 23,130,970 Ordinary
Shares to be admitted to trading on AIM to be issued from time to
time pursuant to the exercise of share options under the Share
Option Scheme conditionally adopted by Chi-Med in 2015 (the "2015
HCML Share Option Scheme"). It is expected that such admission will
become effective on June 17, 2019.
When issued, these Ordinary Shares will be credited as fully
paid and will rank pari passu with the existing Ordinary Shares in
issue.
The sole reason for the above block admission applications is to
replace the Company's previous block admission schemes following
the Company's recent share subdivision which took effect on May 30,
2019.
As at the date of this announcement, the issued share capital of
Chi-Med consists of 666,577,450 Ordinary Shares, with each share
carrying one right to vote and with no shares held in treasury.
This figure of 666,577,450 may be used by shareholders as the
denominator for the calculations by which they could determine if
they are required to notify their interest in, or a change to their
interest in, Chi-Med under the Financial Conduct Authority's
Disclosure Guidance and Transparency Rules. For illustrative
purposes only, the 666,577,450 Ordinary Shares would be equivalent
to 666,577,450 depositary interests (each equating to one Ordinary
Share) which are traded on AIM or, if the depositary interests were
converted in their entirety, equivalent to 133,315,490 ADSs (each
equating to five Ordinary Shares) which are traded on the NASDAQ
Global Select Market.
About Chi-Med
Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical
company which researches, develops, manufactures and markets
pharmaceutical products. Its Innovation Platform, Hutchison
MediPharma, has about 420 scientists and staff focusing on
discovering, developing and commercializing targeted therapeutics
and immunotherapies in oncology and autoimmune diseases. It has a
portfolio of eight cancer drug candidates currently in clinical
studies around the world. Chi-Med's Commercial Platform
manufactures, markets, and distributes prescription drugs and
consumer health products, covering an extensive network of
hospitals across China.
Dual-listed on the AIM market of the London Stock Exchange and
the Nasdaq Global Select Market, Chi-Med is headquartered in Hong
Kong and majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 1). For more information, please
visit: www.chi-med.com.
Forward Looking Statements
This announcement contains forward-looking statements within the
meaning of the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements involve risks and uncertainties. Existing and
prospective investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. For further discussion of these and other risks, see
Chi-Med's filings with the U.S. Securities and Exchange Commission
and on AIM. Chi-Med undertakes no obligation to update or revise
the information contained in this announcement, whether as a result
of new information, future events or circumstances or
otherwise.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President, Corporate Finance & Development +852 2121 8200
Annie Cheng, Vice President, Corporate Finance & Development +1 (973) 567 3786
David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile)
david.dible@citigatedewerogerson.com
Xuan Yang, Solebury Trout +1 (415) 971 9412 (Mobile)
xyang@troutgroup.com
Media Enquiries
UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile)
anthony.carlisle@cdrconsultancy.co.uk
Americas - Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Hong Kong & Asia ex-China - Joseph Chi Lo, Brunswick +852 9850 5033 (Mobile)
jlo@brunswickgroup.com
- Zhou Yi, Brunswick +852 9783 6894 (Mobile)
yzhou@brunswickgroup.com
Mainland China - Sam Shen, Edelman +86 136 7179 1029 (Mobile)
sam.shen@edelman.com
Nominated Advisor
Richard Gray / Atholl Tweedie, Panmure Gordon (UK) Limited +44 (20) 7886 2500
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ARIFTMPTMBBBMAL
(END) Dow Jones Newswires
June 12, 2019 04:18 ET (08:18 GMT)
Hutchison China Meditech (LSE:0J7G)
Historical Stock Chart
From Apr 2024 to May 2024
Hutchison China Meditech (LSE:0J7G)
Historical Stock Chart
From May 2023 to May 2024